AstraZeneca PLC (LON:AZN) Receives Buy Rating From Liberum Capital Analysts

Ltd. boosted its stake in Astrazeneca PLC by 5.5% in the second quarter. Ltd. now owns 220,574 shares of the company's stock worth $7,248,000 after buying an additional 6,818 shares in the last quarter. Acrospire Investment Management LLC raised its position in shares of AstraZeneca plc by 1,078.4% in the third quarter. Finally, Premier Asset Managment LLC boosted its stake in shares of AstraZeneca plc by 83.9% in the third quarter.

Intertek Group plc (LON:ITRK) had its price objective increased by research analysts at Jefferies Group LLC from GBX 4,300 ($52.59) to GBX 4,400 ($53.82) in a research note issued on Thursday. Capital International Investors now owns 20,473,479 shares of the company's stock worth $618,094,000 after buying an additional 3,705,199 shares during the last quarter. Holowesko Partners Ltd. now owns 3,221,000 shares of the company's stock worth $105,842,000 after buying an additional 179,000 shares in the last quarter.

Shares of AstraZeneca plc (NYSE:AZN) opened at 29.50 on Monday. The stock had a trading volume of 3,350,787 shares. The Company has 52-week high of $35.04 and 52-week low of $25.55. The firm's 50-day moving average is GBX 4,372.88 and its 200-day moving average is GBX 4,688.64. The firm has a market capitalization of $74.41 billion, a P/E ratio of 21.31 and a beta of 0.77. The stock of AstraZeneca plc (LON:AZN) earned "Outperform" rating by BNP Paribas on Thursday, July 23. The company reported $1.21 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.62. AstraZeneca plc had a return on equity of 34.30% and a net margin of 15.21%. The business earned $5.59 billion during the quarter, compared to analysts' expectations of $5.43 billion. The company's revenue for the quarter was down 12.7% on a year-over-year basis. Analysts forecast that Astrazeneca PLC will post $1.83 EPS for the current year.

The firm also recently declared a semiannual dividend, which will be paid on Monday, March 20th. Investors of record on Friday, February 17th will be given a dividend of $0.95 per share. This represents a dividend yield of 1.14%.

On 7/29/2016 AstraZeneca plc announced a dividend of $0.44 with an ex dividend date of 8/10/2016 which will be payable on 9/12/2016. This is an increase from Intertek Group plc's previous dividend of $19.40.

Some buy side analysts are also providing their Analysis on AstraZeneca PLC, where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 3 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. TheStreet raised shares of AstraZeneca plc from a "c+" rating to a "b-" rating in a research report on Tuesday, February 28th. For stocks' current month, 15 analysts opted for BUY ratings as compared to 0 opting for SELL in the same period.

Analysts are estimating that Astrazeneca PLC (AZN) to hit $32.07 Price Target in next one year, this mean price is come up through the consensus of analysts.

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products.



Otras noticias